Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: Results from a nested in a cohort case-control study

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 4, 2011, Pages 323-326

  Mandelli, Giovanna ^a   Radaelli, Franco ^a   Paggi, Silvia ^a   Terreni, Natalia ^a   Gola, Gemma ^b   Gramegna, Maria ^b   Bonaffini, Antonino ^b   Terruzzi, Vittorio ^a  

^a VALDUCE HOSPITAL   (Italy)

^b Azienda Sanitaria Locale   (Italy)

Author keywords

aspirin; colorectal cancer; immunochemical fecal occult blood test; screening; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CANCER SCREENING; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OCCULT BLOOD TEST; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL;

AGED; ANTICOAGULANTS; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS;

EID: 79954422134     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283438aac     Document Type: Article

References (13)

1. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365-1371. (Pubitemid 23131388)
2. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour T, et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer. Lancet 1996; 348:1472-1477. (Pubitemid 26400242)
3. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal occult blood test. Lancet 1996; 348:1467-1471. (Pubitemid 26400241)
4. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126:1674-1680. (Pubitemid 38736331)
5. Benson VS, Patnick J, Davies AK, Nadel MR, Smith RA, Atkin WS, International Colorectal Cancer Screening Network. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008; 122:1357-1367. (Pubitemid 351287237)
6. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 2008; 135:380-399.
7. Park DI, Ryu S, Kim Y, Lee SH, Lee CK, Eun CS, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105:2017-2025.
8. Gulløv AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med 1999; 159:1322-1328. (Pubitemid 29293594)
9. Sharma VK, Corder FA, Fancher J, Howden CW. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test. Am J Gastroenterol 2000; 95:3629-3632.
10. Kershenbaum A, Lavi I, Rennert G, Almog R. Fecal occult blood test performance indicators in warfarin-treated patients. Dis Colon Rectum 2010; 53:224-229.
11. Clarke P, Jack F, Carey FA, Steele RJ. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis 2006; 8:389-392. (Pubitemid 43676653)
12. Iles-Shih L, Collins JF, Holub JL, Lieberman DA. Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin. Am J Gastroenterol 2010; 105:2030-2034.
13. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009; 104:933-938.